Sharon Sickafuse

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.

Richard Pazdur, Huanyu Chen, P. Keegan, 2013, The oncologist.